Filtered by tag: Neurological Effects Remove Filter

New MASCC Book: Diagnosis, Management and Emerging Strategies for Chemotherapy-Induced Neuropathy

2021     Coming soon! Edited by MASCC’s own Maryam Lustberg and Charles Loprinzi, this book will be an essential resource for researchers and healthcare providers working with patients experiencing chemotherapy-induced peripheral neuropathy (CIPN).

Read More

Editor's Pick: Cancer-related cognitive impairment in patients with non-central nervous system malignancies: an overview for oncology providers from the MASCC Neurological Complications Study Group

2021    Throughout the year, we will share articles from the MASCC journal Supportive Care in Cancer. The “Editor’s Pick” section, chosen by the journal’s Editor-In-Chief, Dr Fred Ashbury, PhD, will cover a variety of topics to meet the many interests of our membership.

Read More

Study Group Leadership for 2020/2022

2020    MASCC announces the Study Group Leadership changes for 2020/2022. For the full roster of study group leaders, visit individual study groups on the MASCC website.  Be sure to stay in touch with your Study Groups and get involved in their projects. It's the best way to take full advantage of your MASCC membership and work with like-minded colleagues around the world. Contact Study Group Coordinator Leslie Johnson for more information.

Read More

Neurological Complications Study Group Profile

2019    Chair Maryam B. Lustberg, MD, MPH, is a Medical Oncologist and tenured Associate Professor in the College of Medicine at The Ohio State University and a member of the Cancer Control Program at The Ohio State University’s James Comprehensive Cancer Center (OSUCCC). She has specialized in breast cancer and works as a medical oncologist at the Stefanie Spielman Comprehensive Breast Center. She is the Director of Breast Cancer Survivorship and the Medical Director of Cancer Supportive Care Services at OSUCCC and physician champion for the Adolescent and Young Adult Program. She has led numerous clinical trials, including research on the early detection of heart damage in patients treated with chemotherapy. She was recently awarded an R01 from the National Cancer Institute on focused on targeted therapies for the prevention of chemotherapy-induced neuropathy. Maryam has authored or co-authored of numerous research papers on such topics as physicians’ perspectives on survivorship care for older breast cancer survivors, prevention of chemotherapy-induced peripheral neuropathy, and early detection of chemotherapy induced cardiotoxicity in breast cancer survivors. She is a member of the American Society of Clinical Oncology (ASCO) Neuropathy Task Force and the ASCO Survivorship Education Track, and member of Alliance and Southwest Oncology Group Cooperative Group Networks in the USA. In addition to the Neurological Complications Study Group, Maryam is a member of MASCC Study Groups on Nutrition and Cachexia and Survivorship.

Read More

Docetaxel-Induced Peripheral Neuropathy in Breast Cancer Survivors

2015    It is well known that chemotherapy-induced symptoms, including peripheral neuropathy, often lead to the reduction or premature discontinuation of drug dosages in a large proportion of patients. This can mean that patients receive significantly less chemotherapy. The taxanes, paclitaxel and docetaxel, are one class of chemotherapeutic drugs with this effect.

Read More